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Abstract 
 
 Doxorubicin as chemotherapeutic agent causes immunosuppresive. The aim  for this 
study to determine the effect of ethanolic extract of Taraxacum oficinale (ETO) in immunity 
system of Sprague Dawley  rat that induced by doxorubicin to observe the profile of immunity 
cells. Sprague Dawley rats were divided into five groups each groups contain five rats : control 
doxorubicin group, doxorubicin dose 4,67 mg/kgBW+ ETO dose 1000 mg/kgBW, doxorubicin 
dose 4,67 mg/kgBW+ ETO dose 500 mg/kgBW, control extract group, and without treatment. 
Then the number of leukocytes, lymphocytes and neutrophils were analyzed  by hematology 
analyzer, whereas CD8+ T lymphocytes by flowcytometry. Results showed groups of 
doxorubicin combined with ETO dose 1000 mg/kgBW and 500 mg/kgBW increased the number 
of leukocytes, lymphocytes, neutrophils,  cytotoxic CD8 + T cells  T cells compared to control 
doxorubicin group. These data presents that etanolic extract of Jombang leaves has  
immunostimulatory activity and potential as co-chemotherapy agents. Molecullar mechanism 
underlaying it’s immune activity need to be explored in detail. 
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INTRODUCTION  
 
Cancer is a disease caused by the growth of 
body tissue cells that  abnormal and 
uncontrollable. The main treatment is mostly done 
to treat cancer such as surgery, radiation, and 
chemotherapy (Siahaan, 2005). However, 
prolonged use of chemotherapy can cause 
weakening of the immune system (Patel et al., 
2006). 
The use of doxorubicin as an 
chemotheraphy agent is considered effective 
(Frias et al., 2009). However, the use of 
doxorubicin was thinking about some side effects 
such as causing cardiotoxicity (Frias et al. 2009; 
Bustova, 2009), susceptible to disease, hair loss, 
and sore throat. In addition, doxorubicin also 
affects the immune system by reducing the 
expression of IL-α, interferon production γ, 
natural killer cells (NK), lymphocyte proliferation, 
and the ratio of CD4 + / CD8 + (Zhang et al., 
2005). Therefore, we need a compound that works  
synergy with doxorubicin, but can reduce the 
immunosuppressive side effects of doxorubicin. 
Today, we’ve discovered various 
materials which otherwise could increase the 
body's resistance to a disease called as 
immunostimulant. Ethanolic extract of Taraxacum 
oficinale leaves (ETO) is reported able to increase 
the secretion of TNF-α and IL-1 (Kim et al., 
2000; Koo et al., 2004). TNF-α works together 
with IL-1 as functional non-specific immunity 
(Baratawidjaja, 2006). Jeon et al. (2007) also 
figured out that ETO is able to influence the 
antiinflammatory response through the inhibition 
of synthesis of nitric oxide (NO) and inhibition of 
COX-2 expression.Therefore, ETO can be 
expected used as immunostimulatory for 
combination with doxorubicin (co-chemotherapy). 
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The aim for this stydy to find alternative 
safe co-chemotherapy in cancer therapy and 
determine the effect of ETO on immune cells in 
Sprague Dawley rats  induced by doxorubicin 
 
MATERIALS AND METHODS 
 
Taraxacum officinale Extraction 
Taraxacum officinale leaves powder was 
obtained and determined by B2P2TO2T (Balai 
Besar Penelitian dan Pengembangan Tanaman 
Obat dan Obat Tradisional) Tawangmangu, 
Central Java. Powder of  Taraxacum officinale 
leaves (1000 g) was extracted with 70% ethanol 
(10 l) (1:10 b/v). Ethanolic filtrate then 
concentrated by  a rotary evaporator, followed by 
freeze drying to obtain viscous extract (150.7 g). 
 
Animals 
Female, 60 days old, Sprague Dawley, 
weighed from 90 to 120 g were purchased from 
UPHP UGM.  Animals were raised in ambient 
temperature (25-30˚C), fed with pellet and tap 
water. 
 
Design of Experiments  
There were 5 groups, containing 4 rats in 
each group. Concentrated extract was suspended 
in 0.5 % CMC-Na, before being given to the 
animals orally for 7 consecutive day. Doxorubicin 
(Kalbe Farma)  4,67 mg/kgBW were administered 
on intra peritoneal (i.p.) twice a week in day 1
st
 
and 4
th
, while ETO were given everyday for a 
weeks. 
The first group acts as positive control, 
being treated with Doxorubicin (Doxo control 
group). The second group was treated with 
Doxorubicin and ETO 500 mg/kgBW (treatment 
group). The third group was treated with 
Doxorubicin and ETO 1000 mg/kgBW (treatment 
group). The fourth was treated with ETO 1000 
mg/kgBW (ETO control), and the fifth group was 
controlled without treatment. Each rat blood 
sampled two times, on day 0 (pre-treatment) and 
the 8
th
 (post-treatment) through the venous 
ocularis using heparinized capillaries and stored 
in EDTA vacutainers. Then the number of 
leukocytes, lymphocytes and neutrophils were 
determined by hematology analyzer, whereas 
CD8+ lymphocytes by flowcytometry.  
Furthermore, sample preparation is 
performed 5,0 µl whole blood plus 10µL  reagent 
rat antigen CD3 fluorescein isothiocyanate (FITC) 
(Invitrogen) and phycoerythrin (PE) anti-rat 
CD8+ (eBioscience) and then vorteks and stored 
in a dark room for 15 minutes. After that, plus 
450,0 µl lysing solution (BP FACS) for dilution, 
vorteks, then set aside in a dark room for 15 
minutes. The sample is measured by 
flowcytometer (FacsCalibur) and analyzed using 
the program multiset. The data was obtained from 
relative number of CD8+ T cell lymphocytes.  
 
Statistical Methods 
SPSS/PC 13.0 software was used. Multiple 
comparisons were done using one-way ANOVA 
followed by Tuckey Test. The 0.1 level of 
probability was used as the criterion for 
significance. 
 
RESULT 
 
The effects of doxorubicin and/or  ETO on 
the leukocytes, lymphocytes, neutrophils, and 
CD8+ T cell lymphocytes female Sprague Dawley 
rats (Figure 1). In general, the profile of 
hematology analyzer and flowcytometry after 
treatment in the control doxorubicin group, 
doxorubicin+ETO 1000, doxorubicin+ETO 500 
showed decreasing both the number of leukocytes, 
lymphocytes, neutrophils, and T cell lymphocytes, 
CD8+ rather than pre-treatment, whereas the 
control group ETO 1000 and without treatment 
showed increasing both the number of 
leukocytes,lymphocytes, neutrophils, and CD8+ T 
cell than pretreatment.  
Administration of doxorubicin give highest 
decreasing in the number of immune cells. It’s 
showed that doxorubicin has immunosuppressive 
effects (Zhang et al., 2005). Treatment of 
doxorubicin in combination with ETO 1000 
mg/kgBB and ETO 500 mg/kgBB  increased more 
the number of immune cells than doxorubicin 
control group. It showed that the combination of 
doxorubicin with ETO could reduce the side 
effects of doxorubicin in suppressing immune 
system. 
The control extract group and the untreated groups 
of post-treatment showed an increase both the 
number of leukocytes, lymphocytes, neutrophils, 
and CD8+ T cells rather than pre-treatment 
(baseline). Improvement in the control extract 
groups was higher than the without treatment 
group showed that the ability to reduce 
immunosuppressive effects on doxorubicin 
combined with ETO is caused by the capability of 
ETO to enhance the immune system 
(immunostimulatory). Variation of does showed 
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that RTO 500 m/kgBW decrease the number of 
immune cells is lower than ETO 1000 m/kgBW. It 
means that at a dose of 500 mg/kgBW combination 
of doxorubicin with ETO is more effective in 
suppressing the side effects of immunosuppressive 
doxorubicin. So, the effectiveness in reducing the 
immunosuppressive effects are non depending 
dose. 
 
 
 
 
Figure 1. Hematology Analyzer Profile leukocyte immune cell parameters leukocytes(a), lymphocytes (b), 
neutrophils (c), flowcitometry profile of CD8 + T cell lymphocytes (d),. In general, the profile of 
Hematology Analyzer and flowcytometry after treatment in the control group doxo, doxo + ETO 
1000, doxo + ETO 500 showed a decrease both the number of leukocytes, lymphocytes, 
neutrophils, and T cell lymphocytes, CD8 + rather than pre-treatment, whereas the control 
group ETO 1000 and without treatment showed increasing both the number of leukocytes, 
lymphocytes, neutrophils.  
 
 
 
 
 
Table 1. The number of  cells leukocytes, lymphocytes , neutrophils 
 
 
 
 
 
 
Group Leukosit (/µl) Limfosit (/µl) Neutrofil (/µl) 
 
pre treatment post treatment pre treatment post treatment pre treatment post treatment 
Doxo 4,67 mg/kgBW 8475 2125 6475 1450 2000 675 
Doxo+ETO 500 mg/kgBW 6200 3125 4525 2175 1875 950 
Doxo+ETO 1000 mg/kgBW 8433 4467 5325 3600 1333 867 
ETO 1000 mg/kgBW 4975 10600 3225 9075 1750 1525 
without treatment 6550 8025 4700 7225 1850 800 
treatment 
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This result is supported by flowcytometry 
profiles of CD8+ T cells lymphocytes relative (Fig. 
2 and 3). In general, the fluorescence of 
lymphocytes CD8+ T cells (green fluorescence) 
generated in the post-treatment of all groups was 
smaller than pre-treatment. The fluorescence of 
doxorubicin smallest in the control group. Group 
combination of doxorubicin 500 mg/KgBW and 
1000 mg/kg, extract control groups  and without 
treatment groups showed higher fluorescence than 
control doxorubicin group. The green fluoresence 
indicates the relatyve number of CD8+ T cell 
lymphocytes. Then, the relatyve number of CD8+ 
T cell lymphocytes time with the total of 
lymphocytes (Table 1).  
Result shows groups of doxorubicin 
combined with ETO 1000 mg/KgBW and 500 
mg/KgBW have the increas the number of 
leukocytes, lymphocytes, neutrophils,  cytotoxic 
CD8+ T cells  compared to control doxorubicin 
groups. But, only doxorubicin combined with ETO 
500 mg/KgBW treated group has cytotoxic CD8+ 
T cells  differs significantly from control 
doxorubicin. Based on these data, we can conclude 
that administration of  ETO is able to increase the 
number of leukocytes, lymphocytes, neutrophils, 
the number of CD8+  T cell lymphocytes. The 
administration can give a single ETO and a 
combination with doxorubicin showed 
immunostimulatory activity which also can reduce 
the side effects of chemotherapy that can be used 
as a  with agent chemotheraphy. 
 
 
Figure 2. Results of data processing flowcytometry CD8 + T cell lymphocytes post-treatment with the 
multiset. Control doxo group (a); doxo + ETO 1000 (b); doxo + ETO 500 (c); ETO 1000 (d), 
without treatment (e) on the post treatment has a fluorescence that decreasing from pre-
treatment.         green fluorescence indicates the number of CD8 T cell lymphocytes. 
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Table 2. The number of  CD8+  T limfosit cells 
Group 
CD8+ (/µl) 
Pre 
treatment 
Post treatment 
Doxorubicin 930 76,6 
Doxorubicin+ETO 1000 518 112 
Doxorubicin+ETO 500 374 335 
ETO1000 326 776 
Without treatnent 515 618 
 
 
DISCUSIONS 
 
 Doxorubicin is one of the most active 
cytotoxic agents in current use. The clinical 
efficacy of the anthracycline, however, has been 
precluded by immunosupresion (Zhang et. al., 
2005). Free radical generation and lipid 
peroxidation have been suggested to be responsible 
for doxorubicin-induced immunosupression 
(Gewirtz, 1999). 
 In this study prior administration of ETO for 
twice a week of doxorubicin 
notably increase the number of the immune cells of  
female Sprague Dawley rats. Doxorubicin 
administration induced immunosuppresion as 
manifested by highest decreasing in the number of 
immune cells. 
Being polyphenolic compounds, flavonoids 
have shown anti-radical and iron-chelating 
properties in experimental animals (Quiles et. al., 
2002), and thus  would be possible protectors 
against anthracylines-induced immunosupression. 
T. officinale is a source of flavone, luteolin and 
luteolin-3-o-glucoside (Chun and David, 2005). Hu 
and Kitts (2005) reported that T. officinale flower 
extract suppreses both reactive oxygen species and 
nitro oxide and peroxidation lipid in vitro. Our 
findings showed that combination doxorubicin 
with ETO can reduce immunosuppresion effect of 
doxorubicin.  
 This research data can be used as one of the 
scientific evidence for the development of 
Taraxacum officinale leaves become 
phytopharmaca and standardized.    
 
CONCLUSION 
 
Taraxacum officinale leaves ethanolic 
extract  500 mg/kgBW is potentially to develop as 
immunostimulatory agent for co-chemotheraphy 
with doxorubicin. 
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